Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor.
Anandamide (ANA) alters sleep by increasing the amount of time spent in slow wave sleep 2 (SWS2) and rapid eye movement sleep (REMS) at the expense of wakefulness (W) in rats. In this report, we describe a similar effect of ANA when injected itracerebroventricularly (i.c.v.) or into the peduriculopontine tegmental nucleus (PPTg) and the lack of an effect when ANA is administered into the medial preoptic area (MPOA). Furthermore, the i.c.v. or PPTg administration of SR141716A, a CB1 antagonist, or U73122, a PLC inhibitor, 15 min prior to ANA, readily prevents the ANA induced changes in sleep. The present results suggest that a cannabinoid system in the PPTg may be involved in sleep regulation and that the cannabinoid effect is mediated by the CB1 receptor coupled to a PLC second messenger system.
Murillo-Rodríguez
E
E
Grupo de Neurociencias, Depto. de Fisiologia, Facultad de Medicina, Universidad Nacional Autónoma de México, Apdo. Postal 70-250, México D.F. 04510, México.
Cabeza
R
R
Méndez-Díaz
M
M
Navarro
L
L
Prospéro-García
O
O
D000818:Animals; D001095:Arachidonic Acids / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D002186:Cannabinoids / Q000037:antagonists & inhibitors / Q000378:metabolism*; D063388:Endocannabinoids; D004963:Estrenes / Q000494:pharmacology*; D007276:Injections, Intraventricular; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles / Q000494:pharmacology*; D011760:Pyrrolidinones / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000037:antagonists & inhibitors*; D000077285:Rimonabant; D012894:Sleep Stages / Q000187:drug effects* / Q000502:physiology; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors*; D017557:Ventral Tegmental Area / Q000187:drug effects / Q000502:physiology
D001095:Arachidonic Acids; D002186:Cannabinoids; D063388:Endocannabinoids; D004963:Estrenes; D010726:Phosphodiesterase Inhibitors; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D011760:Pyrrolidinones; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; D010738:Type C Phospholipases; D000077285:Rimonabant; C078814:anandamide